Subtype
Male Reproductive System Carcinoma
CI-CAN-00003134Explore in graph →
451 active trials16 approved drugs20 evidence items
- NCIt
- C181196
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003134Explore in graph →
Clinical trials
1,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (190)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY | 39 | Sep 25, 2026 | clinicaltrials |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | recruiting | Phase 3 | 900 | PfizerINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 736 | BioNTech SEINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | recruiting | Phase 3 | 1,209 | NRG OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)(Himalayas-1) | recruiting | Phase 3 | 600 | ORIC PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | recruiting | Phase 3 | 1,260 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | recruiting | Phase 3 | 804 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06717711 | Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers(RCT_LiESWT) | recruiting | Phase 3 | 158 | Regina Elena Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa(BiPASS) | recruiting | Phase 3 | 338 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT06625034 | Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer | recruiting | Phase 3 | 108 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06439225 | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes(OPTION-DDR) | recruiting | Phase 3 | 236 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials